Journal article

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A McArthur, Paul B Chapman, Caroline Robert, James Larkin, John B Haanen, Reinhard Dummer, Antoni Ribas, David Hogg, Omid Hamid, Paolo A Ascierto, Claus Garbe, Alessandro Testori, Michele Maio, Paul Lorigan, Celeste Lebbe, Thomas Jouary, Dirk Schadendorf, Stephen J O'Day, John M Kirkwood, Alexander M Eggermont Show all

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2014

University of Melbourne Researchers



Funding Acknowledgements

We thank the patients who participated in this study. We also thank the clinical trial team for their support in the execution of the trial, and F Hoffmann-La Roche-Genentech for supporting the trial. Medical writing assistance was provided by David Gibson, PhD, of ApotheCom, San Francisco, CA, USA, and funded by F Hoffmann-La Roche. JL is funded by the National Institute for Health Research Biomedical Research Centre for cancer at Royal Marsden Hospital/Institute of Cancer Research. GAM is a practitioner fellow of National Health and Medical Research Council.